This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and determine the recommended phase II dose of PA3-17 injection for this patient population.
Secondary objectives include evaluating the pharmacokinetics/pharmacodynamics, preliminarily assessing clinical efficacy, and evaluating the immunogenicity of the injection.
(1) Aged from 3 to 18 years (inclusive), with no restriction on gender. (2) Expected survival time ≥ 3 months. (3) At screening, Karnofsky Performance Status score (for subjects aged ≥ 16 years) or Lansky Performance Score (for subjects aged < 16 years) > 60 points (see Appendix 4).
Failure to achieve remission after treatment with two or more lines of chemotherapy regimens*.
Two or more episodes of relapse.
Relapse after hematopoietic stem cell transplantation. * Remission criteria: CR and CRi for T-ALL; CR and PR for T-LBL. (6) At screening: ① Abnormal tumor cells are detected in bone marrow and/or peripheral blood by multi-color flow cytometry, regardless of the presence or absence of extramedullary lesions on imaging. Abnormal tumor cells in bone marrow must be CD7-positive; abnormal tumor cells in peripheral blood must be CD7-positive, CD4-negative and CD8-negative.
(1) Patients judged by the investigator to require long-term use of immunosuppressants at screening.
Single group
T cell injection targeting CD7 chimeric antigen receptor
Biological/VaccinePA3-17 injection The subjects,who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1.0\*10\^6,2.0\*10\^6 and 4.0\*10\^6 CAR-T/kg groups in order of sequence.And the subjects will be administered once.
MTD
Maximum tolerated dose
DLT
Dose limiting toxicity
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
